Co-Authors
This is a "connection" page, showing publications co-authored by RENATA FERRAROTTO and PRIYADHARSINI NAGARAJAN.
Connection Strength
1.060
-
Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2023 09 01; 149(9):847-849.
Score: 0.228
-
Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
Score: 0.207
-
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
Score: 0.196
-
Complete Response to Immunotherapy Using Pembrolizumab in a Patient With Conjunctival Squamous Cell Carcinoma With Nodal Metastasis. Ophthalmic Plast Reconstr Surg. 2024 Sep-Oct 01; 40(5):e171-e174.
Score: 0.060
-
Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma. Br J Ophthalmol. 2023 03; 107(3):320-323.
Score: 0.050
-
Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 12 01; 127(23):4413-4420.
Score: 0.049
-
Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603.
Score: 0.048
-
Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177.
Score: 0.047
-
Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer. 2021 04 15; 127(8):1238-1245.
Score: 0.047
-
Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
Score: 0.044
-
Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. Ophthalmic Plast Reconstr Surg. 2019 Jul/Aug; 35(4):350-353.
Score: 0.043
-
Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthalmol. 2019 06; 103(6):775-780.
Score: 0.040